Amylyx Pharmaceuticals
NEWS
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
QurAlis’ first piece of the puzzle is a protein called stathmin-2, which is encoded by the STMN2 gene.
Amylyx’s decision to submit the NDA, announced Wednesday morning, came on the heels of recent discussions with the FDA, including a pre-NDA meeting held on July 15.
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
The Boston-based company announced an infusion of $135 million in Series C funds to support the late-stage development of its lead candidate, AMX0035, for amyotrophic lateral sclerosis.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
JOBS
IN THE PRESS